Treatment of infections, especiaiiy septicemia in hematological patients with HBK

Keisuke Toyama, Shinichiro Okamoto, Hiroshi Uchida, Yasuhiko Ando

研究成果: Article査読

1 被引用数 (Scopus)


HBK, a new aminoglycoside, was evaluated clinically for 19 infections of patients with hematological diseases. HBK was administrated mainly by one-hour drip intravenous infusion at a daily dose 100—400 mg for 3 to 23 days. Daily dose and duration of HBK therapy were modified according to the patient's condition. After one-hour drip intravenous infusion of 100 mg HBK, maximum blood concentrations were distributed from 4.42 µg/ml to 10.98 µg/ml. Two cases with septicemia, 6 possible septicemia and 4 other infections were treated with HBK alone, and 3 septcemia and 4 possible septicemia were treated with HBK combined with other chemotherapy. All 5 cases with septicemia responded to HBK alone or combination chemotherapy In 10 cases with possible septicemia, the clinical response to HBK alone and combination therapy were observed in 4 and 1, respectively. The cases with other infections all responded to HBK alone. The overall response rate was 72%, no significant side effect was observed after the administration of HBK. From the above results, HBK was expected to be useful in the treatment of infection, especially septicemia, of hematological patients.

出版ステータスPublished - 1986

ASJC Scopus subject areas

  • 薬理学(医学)
  • 感染症
  • 薬理学
  • 創薬
  • 腫瘍学


「Treatment of infections, especiaiiy septicemia in hematological patients with HBK」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。